Evidence map›Paper›PMID 40360739›Full record

ArticleCommunications biology2025

AI-guided laser purification of human iPSC-derived cardiomyocytes for next-generation cardiac cell manufacturing.

Prakaimuk Saraithong, Peyton Krajcarski, Yukako Kusaka, Moe Yamada, Junichi Matsumoto, Hailey Cunningham, Sama Salih, Darby Jones, Devika Baddhan, Christian Hausner and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Prakaimuk Saraithong *Frankel Cardiovascular Regeneration Core Laboratory University of Michigan, Ann Arbor, MI, USA.
Peyton Krajcarski *Frankel Cardiovascular Regeneration Core Laboratory University of Michigan, Ann Arbor, MI, USA.
Yukako KusakaKataoka Corporation, Kyoto, Japan.
Moe YamadaKataoka Corporation, Kyoto, Japan.
Junichi MatsumotoKataoka Corporation, Kyoto, Japan.
Hailey CunninghamFrankel Cardiovascular Regeneration Core Laboratory University of Michigan, Ann Arbor, MI, USA.
Sama SalihFrankel Cardiovascular Regeneration Core Laboratory University of Michigan, Ann Arbor, MI, USA.
Darby JonesFrankel Cardiovascular Regeneration Core Laboratory University of Michigan, Ann Arbor, MI, USA.
Devika BaddhanFrankel Cardiovascular Regeneration Core Laboratory University of Michigan, Ann Arbor, MI, USA.
Christian HausnerFrankel Cardiovascular Regeneration Core Laboratory University of Michigan, Ann Arbor, MI, USA.
Justus AnumonwoDepartment of Internal Medicine-Cardiology, University of Michigan, Ann Arbor, MI, USA.
Anthony RosenzweigDepartment of Internal Medicine-Cardiology, University of Michigan, Ann Arbor, MI, USA.ORCID http://orcid.org/0000-0001-6387-0386
Mary M NavarroStemBioSys, Inc., San Antonio, TX, USA.
Luis Villa DiazDepartments of Biological Sciences and Bioengineering, Oakland University, Rochester, MI, USA.ORCID http://orcid.org/0000-0001-5709-9054
Joseph CriscioneDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, USA.
Deok-Ho KimDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, USA. dhkim@jhu.edu.ORCID http://orcid.org/0000-0002-6989-6074
Todd J HerronFrankel Cardiovascular Regeneration Core Laboratory University of Michigan, Ann Arbor, MI, USA. toddherr@stanford.edu.ORCID http://orcid.org/0009-0000-3995-2306

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Current methods for producing cardiomyocytes from human induced pluripotent stem cells (hiPSCs) using 2D monolayer differentiation are often hampered by batch-to-batch variability and inefficient purification processes. Here, we introduce CM-AI, a novel artificial intelligence-guided laser cell processing platform designed for rapid, label-free purification of hiPSC-derived cardiomyocytes (hiPSC-CMs). This approach significantly reduces processing time without the need for chronic metabolic selection or antibody-based sorting. By integrating real-time cellular morphology analysis and targeted laser ablation, CM-AI selectively removes non-cardiomyocyte populations with high precision. This streamlined process preserves cardiomyocyte viability and function, offering a scalable and efficient solution for cardiac regenerative medicine, disease modeling, and drug discovery.

Indexed as

Artificial IntelligenceCell SeparationInduced Pluripotent Stem CellsLasersMyocytes, CardiacCell DifferentiationCells, CulturedHumans

Identifiers

PMID40360739
PMCPMC12075813

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.